MetaCap

Axogen (AXGN) vs CeriBell (CBLL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Axogen (AXGN) has outperformed CeriBell (CBLL) over the past year, gaining 107.5% versus a gain of 79.5%. Axogen is the larger company by market cap ($3.33 billion vs $1.06 billion), about 3.1 times the size, while CeriBell is growing revenue faster (+36.1% vs +20.2%). Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -60.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AXGN+107.48%CBLL+79.49%
+124%+59%-6%
Nov 21, 20251 yearNov 20, 2026
AXGN+278.99%CBLL+9.56%
+297%+113%-71%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AXGN versus CBLL key metrics
MetricAXGNCBLL
Share price$55.75$27.39
Market cap$3.33B$1.06B
1-day change-1.06%+6.37%
YTD return+70.33%+24.90%
1-year return+107.48%+79.49%
5-year return+481.33%—
Forward P/E79.03—
EPS (TTM)$-0.63$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$225.21M$89.06M
Revenue growth (YoY)+20.21%+36.09%
Net income (latest FY)$-15.70M$-53.41M
Gross margin74.31%87.89%
Operating margin-3.49%-65.57%
Net margin-6.97%-59.97%
52-week high$59.72$28.89
52-week low$26.92$14.87
Distance from 52-week high-6.65%-5.19%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+6.31%+15.26%
Average volume1.57M452.64K
Shares outstanding59.73M38.84M
Employees622327
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Axogen is about 3.1 times larger than CeriBell by market value ($3.33B vs $1.06B).
  • AXGN has outperformed CBLL by 28.0 percentage points over the past year.
  • Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -60.0 cents for CeriBell.
  • CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +20.21%).

About Axogen

AXGN stock →

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees

About CeriBell

CBLL stock →

CeriBell, Inc. operates as a medical technology company in the United States.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees

AXGN vs CBLL FAQ

Which is bigger, Axogen or CeriBell?

Axogen (AXGN) is larger, with a market capitalization of $3.33B compared with $1.06B for CeriBell (CBLL).

Which stock has performed better over the past year, AXGN or CBLL?

AXGN returned +107.48% over the past 12 months, compared with +79.49% for CBLL (price return, excluding dividends). Past performance does not predict future results.

Are Axogen and CeriBell in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons